Amoeba SA
Research Amoeba SA (ALMIB) on Bullrun: market cap EUR 28.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALMIB
- ExchangePA
- CountryFrance
- SectorBasic Materials
- IndustryAgricultural Inputs
- CurrencyEUR
- Market capEUR 28.35M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 8.30M
- Free cash flow-EUR 6.95M
Valuation Snapshot
latest market cap is EUR 28.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 8.30M | -EUR 6.95M | n/a | n/a | EUR 4.72M | EUR 12.24M | -EUR 5.36M |
| FY2024 | EUR 0 | -EUR 6.59M | -EUR 4.78M | n/a | -0.13 | EUR 458.94K | EUR 12.07M | -EUR 10.41M |
| FY2023 | EUR 0 | -EUR 14.30M | -EUR 12.59M | n/a | -0.29 | EUR 519.33K | EUR 4.92M | -EUR 3.94M |
| FY2022 | EUR 0 | -EUR 8.02M | -EUR 4.73M | n/a | -0.24 | EUR 5.53M | EUR 2.36M | EUR 8.18M |
| FY2021 | n/a | n/a | n/a | n/a | -0.44 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | EUR 28.35M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Amoeba SA
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.
Related stock research
Other Basic Materials stocks
Frequently asked questions
What is Amoeba SA's market cap?
Amoeba SA's market capitalization is EUR 28.35M.
What does Amoeba SA do?
Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France.